Key result
MAFLD linked to ~67% higher risk of noncalcified coronary plaques.
Why the study?
Since NAFLD was renamed metabolic associated fatty liver disease (MAFLD) in 2020, no studies have evaluated the correlation between MAFLD and coronary atherosclerosis (CAS).
Does metabolic associated fatty liver disease (MAFLD) correlate with coronary atherosclerosis and specific plaque patterns?
Cross-Sectional (n=1,164)
No
Does metabolic associated fatty liver disease (MAFLD) correlate with coronary atherosclerosis and specific plaque patterns?
MAFLD is independently associated with a higher likelihood of noncalcified and mixed coronary plaques on CCTA, suggesting an increased risk of vulnerable coronary atherosclerosis.
Answers are grounded in this paper and cite their sources.
MAFLD may flag higher-risk plaques on CCTA; hypothesis-generating and should not yet change practice or prompt targeted screening.
Background: Nonalcoholic fatty liver disease (NAFLD) is the hepatic manifestation of metabolic syndrome (MetS) and has been shown to be correlated with coronary atherosclerosis (CAS). Since NAFLD was renamed metabolic associated fatty liver disease(MAFLD) in 2020, no studies have evaluated the correlation between MAFLD and CAS. The aim of this study was to evaluate the relationship between MAFLD and CAS. Methods: A total of 1330 patients underwent continuous coronary computed tomography angiography (CCTA) and abdominal ultrasound as part of a routine physical examination. Ultrasonography was used to assess fatty liver, and CCTA was used to assess coronary artery plaques, degree of stenosis, and diseased blood vessels. Univariate and multivariate logistic regression analyses were performed with plaque type and degree of stenosis as dependent variables and MAFLD and traditional cardiovascular risk factors as independent variables to analyze the correlation between MAFLD and CAS. Results: Among the 1164 patients, 680 (58.4%) were diagnosed with MAFLD through a combination of ultrasound and auxiliary examinations. Compared with patients in the non-MAFLD group, patients in the MAFLD group had more cardiovascular risk factors. MAFLD was correlated with calcified plaques, noncalcified plaques, mixed plaques, degree of coronary artery stenosis and multiple coronary artery lesions (p<0.05). After correction for cardiovascular risk factors, MAFLD was correlated with noncalcified plaques (1.673; 95% confidence interval (CI) 1.153-2.430; p=0.007) and mixed plaques (1.543; 95% CI 1.104-2.155; p=0.011). Conclusions: In this study, MAFLD was correlated with cardiovascular risk factors, degree of coronary artery stenosis, multiple coronary artery lesions, and coronary atherosclerotic plaques, particularly noncalcified and mixed plaques, but not with traditional cardiovascular risk factors.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2023) conducted a cross-sectional in Metabolic associated fatty liver disease and coronary atherosclerosis (n=1,164). Metabolic associated fatty liver disease (MAFLD) vs. Non-MAFLD was evaluated on Presence of noncalcified coronary plaques (OR 1.673, 95% CI 1.153-2.430, p=0.007). After adjusting for cardiovascular risk factors, MAFLD was independently associated with an increased risk of noncalcified coronary plaques and mixed plaques.
Synapse has enriched 10 related papers. Consider them for comparative context: